Skip to main content
. 2022 Sep 2;12:980058. doi: 10.3389/fonc.2022.980058

Table 3.

Immunohistochemical PSMA expression.

Overall [177Lu]Lu- therapy
Not eligible Eligible p-value
Patients, n (%) 20 (100%) 17 (85%) 3 (15%)
PSMA IHC available, n (%) 11 (55%) 8 (47.1%) 3 (100%)
H-score
Endothelial cells
Periendothelial cells
Tumor cells
Other non-tumor cells
50 (25-62.5)
0
10 (5-30)
10 (10-20)
30 (17.5-52.5)
0
7.5 (5-25)
10 (8.8-20)
65 (62.5-77.5)
0
20 (10-32.5)
20 (15-30)
0.08
>0.99
0.73
0.35

IHC, immunohistochemistry; PSMA, prostate specific membrane antigen.